Epicrispr Secures Financing to Advance its First-in-Class Epigenetic FSHD Therapy
The money from the oversubscribed Series C round will fund pivotal development of EPI‑321, a clinical-stage epigenetic therapy for FSHD, and supports late-stage development and expansion of manufacturing and pipeline programs.
Epicrispr Biotechnologies has closed an oversubscribed USD 90 million Series C financing round to advance its first-in-class epigenetic therapy, EPI‑321, for facioscapulohumeral muscular dystrophy (FSHD), toward pivotal clinical studies. The closure of the financing round ws announced by the company in an Aug. 11, 2026 press release (1).
FSHD is a progressive genetic condition that results in slowly progressive, and often asymmetric, muscle weakness and is caused by genetic changes that allow the DUX4 gene to be turned on in muscle cells. As one of the most prevalent forms of muscular dystrophy, it impacts approximately 1 in 8,000 individuals globally yet lacks any approved disease-modifying treatments (2). In most people, DUX4 is active only in early development and then epigenetically silenced in adult tissues, but in those affected by FSHD this silencing fails, allowing DUX4 to turn on in muscle cells and trigger cell death and progressive weakness.
Delivered as a single intravenous infusion via an adeno-associated virus capsid (AAVrh74) vector — a serotype clinically validated for targeting muscle tissue — EPI‑321 acts directly within muscle cells. Preclinical evaluation demonstrated robust DUX4 suppression, reduced apoptosis, and enhanced muscle contractility following administration. Early company-reported findings highlight a favorable safety profile alongside exploratory efficacy signals, such as statistically significant gains in lean muscle volume and biomarker adjustments aligned with DUX4 inhibition after a single dose. EPI-321 has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations (3).
“This financing marks a pivotal milestone for Epicrispr as we advance EPI-321 and the next generation of programmable epigenetic medicines,” said Amber Salzman, Ph.D., CEO, Epicrispr Biotechnologies, in a company press release (1). “The strength of this investor syndicate reflects the progress we’ve made in translating our platform into the clinic. This financing positions us to advance EPI-321 into pivotal studies, expand our pipeline and continue building a new class of epigenetic therapies for patients.”
In addition to the pivotal clinical development of EPI‑321, the funding will help accelerate Epicrispr’s pipeline of programmable epigenetic medicines and expand its proprietary Gene Expression Modulation System (GEMS) platform and manufacturing capabilities. GEMS functions as a “mix‑and‑match” system that combines DNA‑targeting modules with epigenetic effector domains to activate or repress genes transiently or durably, without nuclease‑mediated DNA cutting, aiming for a differentiated safety and durability profile versus traditional gene editing.
With around USD 213 million raised to date, Epicrispr is advancing EPI‑321 toward pivotal studies as a potential one‑time, disease‑modifying therapy for FSHD, an indication that still has no approved treatment targeting the underlying DUX4-driven pathology.
References
Epicrispr Biotechnologies. Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD. Press Release, Aug. 11, 2026.
MDA. Facioscapulohumeral Muscular Dystrophy (FSHD). mda.org (accessed Aug. 13, 2026).
Epicrispr Biotechnologies. Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD. Press Release, March 26, 2025.